Latest News

Tucatinib’s new HER2-positive breast cancer maintenance indication extends disease control while requiring close liver monitoring and pharmacist coordination of oral therapy with ongoing antibody treatment.

Impostor syndrome prevalence in oncology pharmacists is a complex topic that is not well described.

This quiz was created in collaboration with PTCE™.

Pharmacy professionals can leverage LinkedIn to build a professional brand, expand meaningful connections, share expertise, and create opportunities for career growth.

An Italian pharmacy student offers an inside look at pharmacy education in Italy, from admission and coursework to oral exams and professional training.

The PD-1 inhibitor is the first immunotherapy approved for stage II and III MSI-H/dMMR locally advanced rectal cancer and may allow eligible patients to avoid chemotherapy, radiation, and surgery.

The once-nightly drop, previously approved to reverse pupil dilation, met its primary end point in 2 phase 3 trials, with conjunctival hyperemia most common.

Public data may help identify drugs associated with shortages, but hospital inventory and purchasing data could make early-warning tools more useful.

Danielle Roman, PharmD, BCOP, FHOPA, explains how ASCO’s updated breast cancer surveillance guideline links follow-up intensity to recurrence risk and creates opportunities for pharmacist involvement.

FDA-approved capivasertib triplet improves rPFS in PTEN-deficient mCSPC; learn dosing, key drug interactions, and managing diarrhea, hyperglycemia, and rash.

Isatuximab on-body injector enables quick, hyaluronidase-free subcutaneous dosing, reducing reactions and easing multiple myeloma clinic workflows.

A summer PCAC vote pushes 6 peptide families toward the 503A bulks list—but the FDA's decision is still pending.

After initial breast cancer treatment, pharmacists can help patients navigate ongoing endocrine therapy, manage persistent adverse effects, and address medication concerns that affect long-term care.

Parminder K. Judge, PhD, explains why eGFR and electrolytes should be monitored when diuretics are added to reach intensive BP targets in patients with CKD

The project maps how flu and HIV proteins enter cells, with the aim of developing longer-lasting vaccines.

Five breast cancer treatment advances in 2026 expand therapeutic options while raising questions.

VAX-31 met all primary end points against PCV20 and PCV21 in the pivotal phase 3 OPUS-1 trial.

Pharmacy teams can prevent early discontinuation by setting clear expectations for when—and how—a medication's benefit will become apparent.

The once-daily device, bioequivalent to the existing prefilled syringe, gives adults with AChR antibody-positive generalized MG a second self-injection option.

A year after FDA approval in heart failure (HF) with LVEF of 40% or higher, new ACC guidance and trial subanalyses are shaping how pharmacists use finerenone.

Neither the lipoprotein(a) [Lp(a)]–lowering antisense oligonucleotide nor the IL-6 inhibitor cut CV events in phase 3, but patients with high Lp(a) may still bring questions to pharmacists.